---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-002350"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:43.702913+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed

## Summary
- Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).
- Q4 adjusted EBITDA guidance $77-81M; cash & short-term investments ~$148M.
- FY2026 revenue guidance $300-320M; DefenCath rev. $150-170M; adj. EBITDA $100-125M.
- CEO Todisco salary raised to $750k (from $665k); target bonus to 75% (from 65%); assumes Chairman role.
- Appoints Mike Seckler as EVP & CCO; Phase 3 ReSPECT data expected Q2 2026; Analyst Day Feb 10.

## SEC filing metadata
- accession: 0001213900-26-002350
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/0001213900-26-002350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/ea0272149-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-002350
- JSON: https://secwatch.observer/filing/0001213900-26-002350.json
- Plain text: https://secwatch.observer/filing/0001213900-26-002350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.